Quintiles-Led Registries User's Guide Published by AHRQ - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Quintiles-Led Registries User's Guide Published by AHRQ


Quintiles-Led Registries User’s Guide Published by AHRQ

Quintiles announced that the U.S. Agency for Healthcare Research and Quality (AHRQ) has published the third edition of “Registries for Evaluating Patient Outcomes: A User’s Guide.” Quintiles’ Real-World & Late Phase Research division has led this effort to create the patient registries reference since 2005. This publication provides a comprehensive guide to the design, operation, analysis and evaluation of patient registries. Nancy A. Dreyer, MPH, Ph.D., senior editor of the handbook and global chief of Scientific Affairs at Quintiles served as a senior editor for the project.  In addition, Dr. Dreyer and Dr. Priscilla Velentgas, senior director of Epidemiology at Quintiles, are also senior editors of a second AHRQ User’s Guide, titled “Developing a Protocol for Observational Comparative Effectiveness Research.”   

The third edition of the registries user’s guide was created in collaboration with more than 240 individuals, representing industry, academia, government and patients. In total, there were 100 chapter contributors, 76 invited peer reviewers, plus public comment, and 109 case example contributors, with some individuals participating in multiple ways. The 11 new chapters address challenges related to design, operations, ethics, analysis, and legal and technical concerns, with topics including:

Click here for the full release.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here